Uroporphyria in the uroporphyrinogen decarboxylase-deficient mouse: Interplay with siderosis and polychlorinated biphenyl exposure
- 1 October 2002
- journal article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 36 (4), 805-811
- https://doi.org/10.1053/jhep.2002.35621
Abstract
Several methods have been used to develop rodent models with the hepatic manifestations of porphyria cutanea tarda (PCT). Acute iron administration or mutations of the hemochromatosis gene (Hfe) have been used to generate hepatic siderosis, a nearly uniform finding in PCT. Heterozygosity for a null mutation at the uroporphyrinogen decarboxylase (Uro-D+/−) locus has been developed to mimic familial PCT in humans. This study examines the interplay of these 2 genetic risk factors and their influence, alone and combined with polychlorinated-biphenyl exposure. Neither an Hfe-null mutation nor iron-dextran administration alone or in combination with polychlorinated biphenyl exposure was porphyrinogenic in a 3-week model using mice wild-type at the Uro-D locus. Homozygosity for an Hfe-null mutation significantly elevated hepatic iron but not to the extent seen with parenteral iron-dextran administration. Homozygosity for an Hfe-null mutation but not iron-dextran administration was porphyrinogenic in animals heterozygous for the Uro-D mutation. Polychlorinated biphenyls were also porphyrinogenic in these animals. Uroporphyria in Uro-D+/− animals was exacerbated by combinations of the homozygous Hfe-null mutation and polychlorinated biphenyls and iron-dextran and polychlorinated biphenyls. In all cases in which uroporphyria developed, a greater degree of experimental uroporphyria was seen in female animals. All elevated hepatic uroporphyrin concentrations were accompanied by depressed uroporphyrinogen decarboxylase activity and the presence of a factor in cytosol that inhibits recombinant human uroporphyrinogen decarboxylase. In conclusion, the expression of the uroporphyric phenotype, dependent on the susceptibility imparted by a genetic mutation, provides a uniquely facile model for dissecting the molecular pathogenesis of the disease.Keywords
Funding Information
- NIH (DK20503)
This publication has 33 references indexed in Scilit:
- Accelerated development of uroporphyria in mice heterozygous for a deletion at the uroporphyrinogen decarboxylase locus.Journal of Biochemical and Molecular Toxicology, 2001
- Co-Inheritance of Mutations in the Uroporphyrinogen Decarboxylase and Hemochromatosis Genes Accelerates the Onset of Porphyria Cutanea TardaJournal of Investigative Dermatology, 2000
- Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tardaBlood, 2000
- Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in north america†Hepatology, 1998
- Porphyria Cutanea TardaSeminars in Liver Disease, 1998
- Uroporphyria produced in mice by iron and 5-aminolevulinic acidBiochemical Pharmacology, 1991
- Chemically-induced formation of an inhibitor of hepatic uroporphyrinogen decarboxylase in inbred mice with iron overloadBiochemical Journal, 1987
- In vitro inhibitory effect on porphyrinogen carboxylyase of liver extracts from tcdd treated miceToxicology Letters, 1984
- Investigations on the presence of porphyrinogen carboxy-lyase inhibitor in the liver of rats intoxicated with hexachlorobenzeneInternational Journal of Biochemistry, 1980
- Cutaneous Porphyria in TurkeyNew England Journal of Medicine, 1960